Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662018 · ClinicalTrials.gov registry record
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07662018: Recruiting study, sponsored by M.D. Anderson Cancer Center.
NCT07662018 is a clinical trial that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07662018 is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Gemcitabine (GEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2033-12-31 |
What NCT07662018 shows while recruiting
NCT07662018 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT07662018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07662018 about?
NCT07662018 is a clinical study titled "Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors". To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
What is the current status of trial NCT07662018?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-06-05. Estimated completion is 2033-12-31.
What interventions are being tested in trial NCT07662018?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Gemcitabine (GEM) (DRUG).
Who is sponsoring clinical trial NCT07662018?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI